Illinois General Assembly - Full Text of HB5051
Illinois General Assembly

Previous General Assemblies

Full Text of HB5051  103rd General Assembly

HB5051 103RD GENERAL ASSEMBLY

 


 
103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024
HB5051

 

Introduced 2/8/2024, by Rep. Jenn Ladisch Douglass

 

SYNOPSIS AS INTRODUCED:
 
215 ILCS 200/52 new

    Amends the Prior Authorization Reform Act. Provides that a health insurance issuer may not require prior authorization for a prescription drug prescribed to a patient by a health care professional for 6 or more consecutive months, regardless of whether the prescription drug is a non-preferred medication pursuant to the patient's health insurance coverage; or for specified prescription drugs, including insulin, human immunodeficiency virus prevention medication; human immunodeficiency virus treatment medication; viral hepatitis medication; estrogen; and progesterone.


LRB103 38175 RPS 68308 b

 

 

A BILL FOR

 

HB5051LRB103 38175 RPS 68308 b

1    AN ACT concerning regulation.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Prior Authorization Reform Act is amended
5by adding Section 52 as follows:
 
6    (215 ILCS 200/52 new)
7    Sec. 52. Prior authorization prohibited. A health
8insurance issuer may not require prior authorization for:
9        (1) a prescription drug prescribed to a patient by a
10    health care professional for 6 or more consecutive months,
11    regardless of whether the prescription drug is a
12    non-preferred medication pursuant to the patient's health
13    insurance coverage;
14        (2) the following prescription drugs or the
15    therapeutic equivalent approved by the United States Food
16    and Drug Administration: insulin; human immunodeficiency
17    virus prevention medication; human immunodeficiency virus
18    treatment medication; viral hepatitis medication;
19    estrogen; and progesterone; or
20        (3) human immunodeficiency virus pre-exposure
21    prophylaxis and post-exposure prophylaxis drugs approved
22    by the United States Food and Drug Administration;
23    Truvada; Harvoni; Descovy; and Apretude.